Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Polisonnografia notturna e monitoraggio del volume respiratorio

30 settembre 2026 aggiornato da: Tufts Medical Center

La valutazione di un monitor del volume respiratorio nei pazienti sottoposti a polisonnografia notturna

Sleep disordered breathing; specifically obstructive sleep apnea (OSA) is a disease affecting 8-12% of the general population and often more than 70% of the bariatric surgical population. OSA is characterized by the repetitive collapse of the upper airway, causing a reduction or cessation in airflow and decreases in oxygen saturation. These events are resolved by arousals from sleep, reducing sleep quality and leading to excessive daytime sleepiness. An in-laboratory polysomnography (PSG) is the gold standard for the diagnosis of OSA.

Previous studies have established obstructive sleep apnea (OSA) as a potential independent risk factor for postoperative complications, adverse surgical outcomes, and longer hospital stays.

Patients with OSA have an increase in postoperative complications, the most frequent being oxygen desaturation, postoperative atelectasis and increased postoperative pain. Despite the clear risks, OSA remains under diagnosed with an estimated 25-30% of patients at a high risk for OSA. It has been suggested that OSA events may be even more frequent post operatively because of the residual effects of anesthesia and the use of potent pain medications such as opioids. Postoperatively apneas often go undetected and untreated. The use of supplemental O2 may mask any desaturations and there is no convenient technology to noninvasively monitor ventilation to detect apnea and hypopnea in post-surgical patients.

New advances in technology and digital signal processing have led to the development of an impedance based Respiratory Volume Monitor (RVM). The RVM (ExSpiron™, Respiratory Motion, Inc.; Waltham, MA) has been shown to provide accurate real-time, continuous, non-invasive measurements of tidal volume (TV), minute ventilation (MV) and respiratory rate (RR). Our main hypotheses are that the non-invasive, impedance-based RVM monitor will accurately reflect TV, RR and MV during sleep and will detect apneas and hypopneas accurately.

Panoramica dello studio

Stato

Attivo, non reclutante

Descrizione dettagliata

This is an observational pilot study to evaluate the clinical applicability of the ExSpiron Respiratory Volume Monitor (RVM) in patients with suspected sleep apnea. Previous work has demonstrated the ability of the RVM to provide non-invasive, real-time, continuous measurements of respiratory parameters (MV, TV, and RR) but those studies have not specifically looked at patients during sleep or patients with sleep disordered breathing.

Previously there was no device capable of providing, continuous, non-invasive, real time measurements of ventilatory status such as minute ventilation, tidal volume and RR. The ExSpiron system utilizing impedance based technology and proprietary algorithms (Respiratory Motion Inc., Waltham, MA) have been developed to obtain these measurements.

Respiratory Motion, Inc. has previously evaluated ExSpiron measurements of respiratory parameters (MV, TV and RR) in studies of adult volunteer subjects. Stimulus leads delivered an alternating minimal current (1.5 mA) at a frequency of 50 kHz and recording leads recorded differential voltages to calculate impedance. Subject data (height, weight, age, gender, chest circumference) were measured. The studies showed that using the optimal lead placement configuration, algorithms based on chest wall impedance and respiratory pattern analysis provided provided RVM measurements and ExSpiron curves which correlated strongly with spirometry volumes and spirometry curves.

A large percentage of patients in the general surgical population have undiagnosed OSA. This population is at increased risk of adverse perioperative respiratory complications. Assessment and management of perioperative respiratory function and early intervention when indicated is a multifaceted, complex task often complicated by the unavailability of an accurate and continuous monitoring system that can demonstrate apnea and hypopnea to guide clinical decision making. The ExSpiron system is designed for these patients and is intended to address some of the limitations of the current generation of hospital monitors as listed below:

In the, non-ventilated patient, current monitoring devices do not provide objective non-invasive, continuous real time measurements of important respiratory parameters MV, TV and RR that reflect respiratory competence, nor do they provide adequate assessment of apnea and hypopnea.

Current monitoring of non-intubated patients mostly relies on oximetry data, subjective clinical assessment which measures respiration and not ventilation and rarely transcutaneous CO2 measurements. In appropriate clinical settings, the ExSpiron system can provide direct quantitative measure of ventilation (MV, TV and RR) that can be used in the detection of apnea and hypopnea.

Precise apnea and hypopnea assessment.

Most if not all of the gaps left by current respiratory assessment technologies may be filled by a non-invasive monitor such as the one proposed for use in this study. There are many potential applications for this technology including: use in peri-procedural environment to evaluate the effects of medication on ventilation and detection of apnea/hypopnea. In addition, it may be useful in clinical decision making regarding medication adjustments of pain management protocols, evaluation ventilatory status prior to extubation and evaluation of the need for reintubation, but also trending of respiratory patterns to avoid risky emergency airway management interventions.

New advances in technology and digital signal processing have led to the development of an impedance based Respiratory Volume Monitor (RVM). The RVM (ExSpiron™, Respiratory Motion, Inc.; Waltham, MA) has been shown to provide accurate real-time, continuous, non-invasive measurements of tidal volume (TV), minute ventilation (MV) and respiratory rate (RR). Our main hypotheses are that the non-invasive, impedance-based RVM monitor will accurately reflect TV, RR and MV during sleep and will detect apneas and hypopneas accurately.

Main Hypothesis: The ExSpiron monitor accurately reflects apnea and hypopnea events compared to standard polysomnography. The ExSpiron monitor is able to distinguish between central and obstructive apneic events.

Secondary Hypothesis: 1) Correlation of MV% as compared to % predicted with comorbidities (e.g. hypertension and metabolic syndrome), 2)Correlation of MV changes as compared to MV% predicted with oxygen desaturation index (ODI), 3) evaluation breathing patterns before and after obstruction, 4) evaluation of breathing patterns in different types of apnea (central, obstructive and mixed).

Tipo di studio

Osservativo

Iscrizione (Stimato)

80

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02111
        • Tufts Medical Center

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

All adult patients referred to the sleep laboratory at Tufts Medical Center for a standard polysomnogram (PSG) are eligible to be recruited.

Descrizione

Inclusion Criteria:

  • Adult Patients referred to the sleep lab for a polysomnography for suspicion of sleep disordered breathing aged ≥ 18 years. Ability to provide written informed consent.

Exclusion Criteria:

- Patients not competent to give informed consent, patients with implantable electronic devices, such as pacemakers, stimulators, etc. pregnant or lactating women.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Lasso di tempo
Concordanza tra il numero e la durata degli eventi di apnea misurati come AHI (indice di apnea-ipopnea) valutato mediante polisonnografia standard rispetto al monitor Exspiron
Lasso di tempo: Durata dello studio polisonnografico, di solito 1 valutazione durante la notte
Durata dello studio polisonnografico, di solito 1 valutazione durante la notte

Misure di risultato secondarie

Misura del risultato
Lasso di tempo
Capacità del monitor Exspiron di distinguere tra eventi di apnea centrale e ostruttiva. Non ci sono unità di misura per questo confronto
Lasso di tempo: Durata dello studio polisonnografico, di solito 1 valutazione durante la notte
Durata dello studio polisonnografico, di solito 1 valutazione durante la notte

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Collaboratori

Investigatori

  • Investigatore principale: Roman Schumann, MD, Tufts Medical Center

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 giugno 2013

Completamento primario (Stimato)

31 dicembre 2027

Completamento dello studio (Stimato)

31 luglio 2028

Date di iscrizione allo studio

Primo inviato

26 settembre 2014

Primo inviato che soddisfa i criteri di controllo qualità

19 novembre 2014

Primo Inserito (Stimato)

20 novembre 2014

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

5 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

30 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi